ストックスクリーナーアプリを入手
4.23
0.24%
0.01
アフターアワーズ：
4.30
0.07
+1.65%
前日終値:
$4.22
開ける：
$4.2
24時間の取引高:
44,419
Relative Volume:
1.42
時価総額：
$31.41M
収益：
-
当期純損益:
$-101.87M
株価収益率:
-3.00
EPS:
-1.41
ネットキャッシュフロー:
$-83.46M
1週間 パフォーマンス:
-1.63%
1か月 パフォーマンス:
+7.09%
6か月 パフォーマンス:
-43.52%
1年 パフォーマンス:
-45.26%
1日の値動き範囲:
$4.04
$4.455
1週間の範囲:
$3.82
$4.455
52週間の値動き範囲:
$3.6201
$9.18
Kezar Life Sciences Inc Stock (KZR) Company Profile
名前
Kezar Life Sciences Inc
セクター
電話
650-822-5600
住所
4000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO, CA
KZR を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
KZR
Kezar Life Sciences Inc
|
4.23 | 31.41M | 0 | -101.87M | -83.46M | -1.41 |
|
VRTX
Vertex Pharmaceuticals Inc
|
439.37 | 128.45B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
575.63 | 65.17B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
560.90 | 40.09B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
270.19 | 35.67B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
233.25 | 27.44B | 3.81B | -644.79M | -669.77M | -6.24 |
Kezar Life Sciences Inc Stock (KZR) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2023-08-11 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2023-03-16 | ダウングレード | William Blair | Outperform → Mkt Perform |
| 2021-12-08 | 開始されました | Wells Fargo | Overweight |
| 2018-07-16 | 開始されました | Jefferies | Buy |
| 2018-07-16 | 開始されました | Wells Fargo | Outperform |
| 2018-07-16 | 開始されました | William Blair | Outperform |
すべてを表示
Kezar Life Sciences Inc (KZR) 最新ニュース
(KZR) Trading Signals - news.stocktradersdaily.com
Kezar Life Sciences, Inc. (NASDAQ:KZR) Shares Purchased by JPMorgan Chase & Co. - Defense World
Kezar Life Sciences Inc expected to post a loss of $2.60 a shareEarnings Preview - TradingView
Geode Capital Management LLC Lowers Position in Kezar Life Sciences, Inc. (NASDAQ:KZR) - Defense World
Kezar Life Sciences (KZR) Expected to Announce Quarterly Earnings on Thursday - Defense World
(KZR) Technical Data - news.stocktradersdaily.com
Kezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - Business Wire
Trend Tracker for (KZR) - news.stocktradersdaily.com
Kezar Life Sciences stock hits 52-week low at $4.36 By Investing.com - Investing.com South Africa
Kezar Life Sciences stock hits 52-week low at $4.36 - Investing.com
Polymyositis Market Predicted to See Upsurge Through 2034, - openPR.com
Kezar Life Sciences Appoints New Principal Accounting Officer - TipRanks
What is William Blair’s Forecast for KZR Q1 Earnings? - Defense World
KZR stock touches 52-week low at $5.20 amid market challenges By Investing.com - Investing.com South Africa
KZR stock touches 52-week low at $5.20 amid market challenges - Investing.com Australia
Kezar Life Sciences Announces Positive Topline Results from the PORTOLA Phase 2a Trial Evaluating Zetomipzomib for the Treatment of Patients with Autoimmune Hepatitis (AIH) and Reports Fourth Quarter and Year End 2024 Financial Results - BioSpace
Kezar reports positive AIH trial results, financials for 2024 By Investing.com - Investing.com South Africa
Promising Clinical Trial Results and Safety Profile Justify Buy Rating for Kezar Life Sciences - TipRanks
Kezar stock drops on Q4 results, trial data (KZR:NASDAQ) - Seeking Alpha
Kezar Life Sciences Touts Positive Data From Mid-Stage Study For Chronic Liver Disease Drug Candidate - Benzinga
Kezar reports positive AIH trial results, financials for 2024 - Investing.com India
Kezar Life Sciences Inc reports results for the quarter ended December 31Earnings Summary - TradingView
KEZAR LIFE SCIENCES Earnings Results: $KZR Reports Quarterly Earnings - Nasdaq
Breakthrough in Autoimmune Hepatitis: Kezar's Drug Achieves 36% Response Rate While Placebo Shows Zero - Stock Titan
Kezar Life Sciences to Present Topline Results from the PORTOLA Phase 2a Trial Evaluating Zetomipzomib for the Treatment of Patients with Autoimmune Hepatitis on March 25, 2025 - BioSpace
Amundi Sells 74,019 Shares of Kezar Life Sciences, Inc. (NASDAQ:KZR) - Defense World
KEZAR LIFE SCIENCES INC- The GF Score's 5 Key Aspects of Analysis - GuruFocus.com
How the (KZR) price action is used to our Advantage - news.stocktradersdaily.com
Dermatomyositis Drug Market 2034: Clinical Trials, EMA, PDMA, FDA Approvals, Treatment Market, Prevalence, Medication, Statistics, Therapies, Companies by DelveInsight - The Globe and Mail
Kezar Life Sciences Inc expected to post a loss of $2.88 a shareEarnings Preview - TradingView
Kezar Life Sciences’ (KZR) Outperform Rating Reiterated at William Blair - Defense World
Kezar stock rating raised to Outperform at William Blair By Investing.com - Investing.com UK
Dermatomyositis Market Generated Opportunities, Future Scope - openPR
(KZR) On The My Stocks Page - Stock Traders Daily
Kezar Life Sciences (KZR) Stock Price, News & Analysis - MarketBeat
Activist investor threatens Peninsula drug maker's merger plans - The Business Journals
Kezar Life Sciences to Present at Virtual KOL Event Hosted by William Blair on Zetomipzomib Clinical Development in Autoimmune Hepatitis and Provide a Safety Update from the PALIZADE Trial for Lupus Nephritis on February 27, 2025 - Business Wire
Objective long/short (KZR) Report - Stock Traders Daily
Kezar Life Sciences files for $400M mixed securities shelf - MSN
Autoimmune Hepatitis Market Growth to Accelerate in Forecast - openPR
Kezar Life Sciences Files $400 Million Mixed Securities Shelf -February 05, 2025 at 05:55 pm EST - Marketscreener.com
Kezar Life Sciences, Inc. (NASDAQ:KZR) Short Interest Update - Defense World
Kezar reports preliminary year-end financial position - Investing.com
Wells Fargo & Company Issues Pessimistic Forecast for Kezar Life Sciences (NASDAQ:KZR) Stock Price - Defense World
HC Wainwright Issues Pessimistic Estimate for KZR Earnings - Defense World
Q4 EPS Estimate for Kezar Life Sciences Decreased by Analyst - MarketBeat
Kezar Life Sciences updates shareholder rights agreement - Investing.com
Kezar Life Sciences Inc (KZR) 財務データ
収益
当期純利益
現金流量
EPS
4.10%
大文字化:
|
ボリューム (24 時間):